RhumbLine Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.56M | Sell |
305,520
-7,894
| -3% | -$188K | 0.01% | 1201 |
|
|
2025
Q4 | $7.32M | Sell |
313,414
-16,888
| -5% | -$376K | 0.01% | 1208 |
|
|
2025
Q3 | $6.51M | Buy |
330,302
+1,224
| +0.4% | +$25.2K | 0.01% | 1293 |
|
|
2025
Q2 | $7.14M | Buy |
329,078
+18,510
| +6% | +$437K | 0.01% | 1223 |
|
|
2025
Q1 | $7.53M | Sell |
310,568
-1,752
| -0.6% | -$39.5K | 0.01% | 1150 |
|
|
2024
Q4 | $6.52M | Buy |
312,320
+952
| +0.3% | +$20.5K | 0.01% | 1284 |
|
|
2024
Q3 | $6.19M | Sell |
311,368
-12,401
| -4% | -$230K | 0.01% | 1311 |
|
|
2024
Q2 | $5.02M | Buy |
323,769
+10,805
| +3% | +$168K | ﹤0.01% | 1398 |
|
|
2024
Q1 | $4.99M | Buy |
312,964
+24,043
| +8% | +$362K | ﹤0.01% | 1427 |
|
|
2023
Q4 | $4.86M | Sell |
288,921
-3,265
| -1% | -$44.6K | 0.01% | 1425 |
|
|
2023
Q3 | $3.42M | Buy |
292,186
+4,624
| +2% | +$61.9K | ﹤0.01% | 1569 |
|
|
2023
Q2 | $3.86M | Buy |
287,562
+6,781
| +2% | +$97.6K | ﹤0.01% | 1532 |
|
|
2023
Q1 | $4.66M | Buy |
280,781
+16,440
| +6% | +$271K | 0.01% | 1367 |
|
|
2022
Q4 | $4.92M | Buy |
264,341
+6,040
| +2% | +$93K | 0.01% | 1287 |
|
|
2022
Q3 | $3.31M | Buy |
258,301
+147,517
| +133% | +$1.75M | ﹤0.01% | 1472 |
|
|
2022
Q2 | $777K | Sell |
110,784
-17,169
| -13% | -$126K | ﹤0.01% | 2263 |
|
|
2022
Q1 | $1.06M | Sell |
127,953
-20,530
| -14% | -$145K | ﹤0.01% | 2110 |
|
|
2021
Q4 | $1M | Sell |
148,483
-1,089
| -0.7% | -$7.16K | ﹤0.01% | 2208 |
|
|
2021
Q3 | $793K | Buy |
149,572
+2,181
| +1% | +$11.9K | ﹤0.01% | 2338 |
|
|
2021
Q2 | $847K | Buy |
147,391
+27,845
| +23% | +$144K | ﹤0.01% | 2319 |
|
|
2021
Q1 | $551K | Sell |
119,546
-6,740
| -5% | -$26.8K | ﹤0.01% | 2444 |
|
|
2020
Q4 | $422K | Buy |
126,286
+7,130
| +6% | +$24K | ﹤0.01% | 2506 |
|
|
2020
Q3 | $354K | Sell |
119,156
-16,805
| -12% | -$65.7K | ﹤0.01% | 2447 |
|
|
2020
Q2 | $628K | Buy |
135,961
+9,701
| +8% | +$43.6K | ﹤0.01% | 2247 |
|
|
2020
Q1 | $486K | Buy |
126,260
+115
| +0.1% | +$472 | ﹤0.01% | 2172 |
|
|
2019
Q4 | $473K | Buy |
126,145
+753
| +0.6% | +$3.52K | ﹤0.01% | 2385 |
|
|
2019
Q3 | $666K | Sell |
125,392
-790
| -0.6% | -$4.21K | ﹤0.01% | 2220 |
|
|
2019
Q2 | $485K | Buy |
126,182
+2,937
| +2% | +$12.7K | ﹤0.01% | 2373 |
|
|
2019
Q1 | $629K | Sell |
123,245
-3,454
| -3% | -$10.2K | ﹤0.01% | 2231 |
|
|
2018
Q4 | $243K | Buy |
126,699
+42,199
| +50% | +$121K | ﹤0.01% | 2638 |
|
|
2018
Q3 | $319K | Sell |
84,500
-6,225
| -7% | -$19.5K | ﹤0.01% | 2484 |
|
|
2018
Q2 | $283K | Buy |
90,725
+23,383
| +35% | +$70.9K | ﹤0.01% | 2562 |
|
|
2018
Q1 | $161K | Buy |
67,342
+4,825
| +8% | +$16K | ﹤0.01% | 2650 |
|
|
2017
Q4 | $244K | Sell |
62,517
-14,279
| -19% | -$47.2K | ﹤0.01% | 2547 |
|
|
2017
Q3 | $194K | Buy |
76,796
+1,095
| +1% | +$3K | ﹤0.01% | 2746 |
|
|
2017
Q2 | $209K | Buy |
+75,701
| New | +$158K | ﹤0.01% | 2733 |
|
|
2016
Q2 | – | Sell |
-76,641
| Closed | -$90K | – | 2989 |
|
|
2016
Q1 | $90K | Buy |
76,641
+1,425
| +2% | +$2.21K | ﹤0.01% | 2912 |
|
|
2015
Q4 | $184K | Buy |
75,216
+6,710
| +10% | +$19.2K | ﹤0.01% | 2824 |
|
|
2015
Q3 | $206K | Buy |
68,506
+3,741
| +6% | +$16.1K | ﹤0.01% | 2774 |
|
|
2015
Q2 | $267K | Buy |
+64,765
| New | +$258K | ﹤0.01% | 2735 |
|
Other funds holding CPRX
VCM
DM
VPM
RhumbLine Advisers's CPRX Position: Q1 2026 in Review
RhumbLine Advisers reduced its Catalyst Pharmaceutical (CPRX) stake by 2.5% in Q1 2026, selling an estimated $188K and leaving 305,520 shares worth $7.56M. The position accounts for 0.01% of the portfolio, ranked #1201.
RhumbLine Advisers first reported a position in CPRX in Q2 2015 and has held it in 40 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- RhumbLine Advisers held 305,520 shares of Catalyst Pharmaceutical worth $7.56M as of Q1 2026.
- RhumbLine Advisers sold 7,894 Catalyst Pharmaceutical shares in Q1 2026, an estimated $188K.
- Catalyst Pharmaceutical made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1201 holding.
- RhumbLine Advisers first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 40 quarters since.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.